A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie jednego z czterech rodzajów raka: raka wątroby, raka żołądka z podwyższonym markerem AFP, guza z komórek zarodkowych lub raka płuc z markerem GPC3
- •Nowotwór nie może być wyleczony operacją i rozprzestrzenił się lub jest w zaawansowanym stadium
- •Wyraźnie widoczny guz widoczny w badaniach obrazowych
- •Ogólny stan zdrowia wystarczająco dobry do podjęcia leczenia
- •Sprawne funkcje wątroby, nerek i innych ważnych narządów
- •Brak leczenia skierowanego na białko GPC3 lub receptory 4-1BB w przeszłości
✗ Disqualifies
- •Przerzuty nowotworu do opon mózgowych lub niekontrolowane ogniska w mózgu
- •Aktywna choroba autoimmunologiczna lub jej historia
- •Inny nowotwór zdiagnozowany w ciągu ostatnich 2 lat, z wyjątkiem badanego tutaj typu raka
- •Wcześniejsze leczenie lekami skierowanymi na GPC3 lub 4-1BB
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (47)
City of Hope Phoenix Cancer Center
Goodyear, United States
City of Hope National Medical Center
Duarte, United States
City of Hope Chicago Cancer Center
Zion, United States
Memorial Sloan Kettering Cancer Center Mskcc
New York, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, United States
Scri Oncology Partners
Nashville, United States
The University of Texas Md Anderson Cancer Center
Houston, United States
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
Porto Alegre, Brazil
Hospital Da Bahia
Salvador, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil
Anhui Provincial Hospital
Hefei, China
Chongqing University Cancer Hospital
Chongqing, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, China
Zhujiang Hospital of Southern Medical University
Guangzhou, China
Nanfang Hospital of Southern Medical University
Guangzhou, China
Guangxi Medical University Cancer Hospital Wuxiang Branch
Nanning, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Harbin Medical University Cancer Hospital
Harbin, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Hunan Cancer Hospital
Changsha, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch
Nanchang, China
Sichuan Cancer Hospital and Institute
Chengdu, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Lishui Central Hospital
Lishui, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Hopital Beaujon
Clichy, France
Centre Hospitalier Universitaire Nantes Hotel Dieu
Nantes, France
Institut Gustave Roussy
Villejuif, France
Irccs Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy
Iov Istituto Oncologico Veneto Irccs
Padova, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Irccs Humanitas Research Hospital
Rozzano, Italy
Kindai University Hospital
Sakai, Japan
Tokyo Metropolitan Komagome Hospital
Bunkyoku, Japan
Cancer Institute Hospital of Jfcr
Kotoku, Japan
Auckland City Hospital
Auckland, New Zealand
Hospital Oncologico
Rio Piedras, Puerto Rico
Chungbuk National University Hospital
Cheongju-si, South Korea
Cha Bundang Medical Center, Cha University
BundangGu SeongnamSi, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Samsung Medical Center
GangnamGu, South Korea
Severance Hospital Yonsei University Health System
SeodaemunGu, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
SongpaGu, South Korea
Trial contact
Study Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.